Royal Blood Announces U.S. Tour & New Album, Shares First Single

first_imgBritish rock band Royal Blood have announced a new album How Did We Get So Dark? due out June 16, 2017, via Warner Bros. Records. In support of this, the duo have shared the album’s lead single “Lights Out” with an accompanied music video. They’ve also announced a slew of United States tour dates, kicking off June 2 at the Paradise Rock Club in Boston, MA and will extend through August 16 at The Wiltern in Los Angeles, with festival appearances at The Governors Ball in New York City, Glastonbury, Eden Sessions, and Japan’s Summer Sonic Festival.Watch “Lights Out” below:Tickets for all dates will be available for purchase starting at 9:00 AM local time on Friday, April 28th. See the full schedule below:Royal Blood U.S. Live Dates2ndJune – Paradise Rock Club, Boston, MA2ndJune – 4thJune – Governor’s Ball, New York, NY6thJune – 9:30 Club, Washington, DC7thJune – Union Transfer, Philadelphia, PA9thJune – St. Andrews Hall, Detroit, MI10thJune – Newport Music Hall, Columbus, OH11thJune – Bonnaroo Music Festival, Manchester, TN31stJuly – Upstate Concert Hall, Buffalo, NY3rdAug – Bogart’s, Cincinnati, OH5thAug – Lollapalooza, Chicago, IL8thAug – Commodore Ballroom, Vancouver, BC9thAug – Showbox, Seattle, WA10thAug – Roseland Theater, Portland, OR12thAug – Outside Lands, San Francisco, CA13thAug – The Observatory, Santa Ana, CA15thAug – The Observatory North Park, San Diego, CA16thAug – The Wiltern, Los Angeles, CAlast_img read more

BPOM approves emergency use of antiviral drugs to treat COVID-19 patients

first_imgMeanwhile drugmaker Gilead Sciences said in a statement that a five-day course of the remdesivir sped up recovery in moderately ill patients with pneumonia from COVID-19. The drug has reportedly been administered to United States President Donald Trump, who was announced COVID-19 positive last Friday.BPOM head Penny K Lukito expects that they EUA issuance will help accelerate access to those drugs for hospitals treating COVID-19 patients.“Hopefully, the drugs will help improve COVID-19 recovery rates and bring down the mortality rate from the pandemic,” Penny said in a statement on Tuesday.She said she hoped doctors and health workers would cooperate in monitoring the efficacy and safety of those drugs under pharmacovigilance.The World Health Organization defines pharmacovigilance (PV) as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.All pharmacovigilance reports will be received by the BPOM and evaluated periodically.If there is an increasing trend of side effect, the BPOM will immediately communicate the risk and revoke the EUA, the statement further said.Since March, the BPOM periodically searches the internet to detect any disinformation regarding drugs claimed to cure COVID-19. It had found more than 46,000 links, including 2,645 links of people illegally selling what they claim are COVID-19 drugs.Upon such findings, the BPOM recommends that the Indonesian E-Commerce Association (IDEA) and Communications and Information Ministry take down those links. (iwa) Topics : Data from the Office of the Coordinating Maritime Affairs and Investment Minister show that the government had previously given contractors the go-ahead to import COVID-19 medication such as remdesivir, favipiravir, oseltamivir and lopinavir-ritonavir, all of which will be distributed directly to hospitals treating coronavirus patients.The data show that, by the end of 2020, the government expects to secure 670,000 vials of remdesivir from foreign sources, but it also expects the drug to be manufactured in the country starting in November.In late September, Reuters reported that a late-stage study by Fujifilm Holdings Corps of its antiviral drug Avigan showed that it reduced recovery times for COVID-19 patients with nonsevere symptoms.The Phase 3 clinical study of 156 patients in Japan showed that those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group. The Food and Drug Monitoring Agency (BPOM) has issued emergency use authorization (EUA) for two antiviral drugs, favipiravir and remdesivir, to treat COVID-19 patients.The BPOM also granted permits in September to several pharmaceutical companies to produce the drugs. PT Beta Pharmacon (Dexa Group) received a permit to produce favipiravir, locally sold under the Avigan brand. State-owned drug manufacturer PT Kimia Farma received the permit to produce a generic favipiravir product, tempo.co reported on Wednesday.Meanwhile, permits to produce remdesivir have been granted to PT Amarox Pharma Global, which is a subsidiary of India’s leading generic drug maker Hetero, as well as to state-owned pharmaceutical firm PT Indofarma and local private firm PT Dexa Medica.center_img Editor’s note: This article is part of a public campaign by the COVID-19 task force (Satgas COVID-19) to raise people’s awareness about the pandemic. #covid19taskforce #mothermessage #wearmask #keepyourdistance #washyourhand #socialdistance #avoidcrowd #usesoaplast_img read more